BG45

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407158

CAS#: 926259-99-6

Description: BG45 is a potent and selective HDAC3 inhibitor inhibitor with selectivity for HDAC3 (IC50 = 289 nM) over HDAC1, 2. BG45 did not inihibit HDAC6. BG45 signigicantly inhibited tumor growth in a mouse model of multiple myeloma either alone and synergistically in combination with bortezomib. HDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM.


Price and Availability

Size
Price

10mg
USD 110
100mg
USD 450
1g
USD 1950
Size
Price

25mg
USD 150
200mg
USD 750
2g
USD 2950
Size
Price

50mg
USD 250
500mg
USD 1250
5g
Ask price

BG45, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 407158
Name: BG45
CAS#: 926259-99-6
Chemical Formula: C11H10N4O
Exact Mass: 214.08546
Molecular Weight: 214.23
Elemental Analysis: C, 61.67; H, 4.71; N, 26.15; O, 7.47


Synonym: BG45; BG-45; BG 45.

IUPAC/Chemical Name: N-(2-Aminophenyl)pyrazine-2-carboxamide

InChi Key: LMWPVSNHKACEKW-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H10N4O/c12-8-3-1-2-4-9(8)15-11(16)10-7-13-5-6-14-10/h1-7H,12H2,(H,15,16)

SMILES Code: O=C(C1=NC=CN=C1)NC2=CC=CC=C2N


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura
N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG,
Hideshima T, Anderson KC. Histone deacetylase 3 as a novel therapeutic target in
multiple myeloma. Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub
2013 Aug 5. PubMed PMID: 23913134; PubMed Central PMCID: PMC4165599.